'4 Trillion Club' Samsung Bio, This Year's Revenue Forecast Reaches 5.5 Trillion Won

Three-Pillar Expansion Strategy: Production Capacity, Portfolio, and Global Bases

Samsung Biologics announced a sales forecast showing 20-25% growth compared to the previous year. The sales forecast for this year is KRW 5.5705 trillion (based on the median value within the expected sales range). Having achieved record-high performance last year, Samsung Biologics expects to maintain steady growth through stable business expansion in 2025 as well.

According to Samsung Biologics' disclosure on the 22nd, as of the end of 2024, consolidated assets stood at KRW 17.3363 trillion, equity at KRW 10.9047 trillion, and liabilities at KRW 6.4316 trillion. The debt ratio was 59.0%, and the borrowings ratio was 12.3%.

Samsung Biologics is continuing its achievements this year, including signing a record-breaking order contract worth approximately KRW 2 trillion with a European pharmaceutical company. Last year, it signed three consecutive contracts worth KRW 1 trillion each in major global markets such as the United States, Europe, and Asia, surpassing a cumulative annual order amount of KRW 5 trillion. Since its founding, the total cumulative order amount is approximately USD 17.6 billion.

Meanwhile, Samsung Biologics currently has secured 17 out of the top 20 global pharmaceutical companies as clients.

Samsung Biologics plans to continue its growth this year through a three-pronged expansion strategy focusing on production capacity, portfolio, and global bases.

First, it is accelerating the expansion of production capacity to proactively respond to the increasing demand for biopharmaceuticals. Currently, the 5th plant with a capacity of 180,000 liters is under construction, aiming to start operations in April this year. Upon completion of the 5th plant, Samsung Biologics’ total production capacity will reach 784,000 liters.

Investment is also being made to expand the portfolio. Last year, Samsung Biologics strengthened its contract development organization (CDO) competitiveness by launching five new technology platforms and customized service packages, and is proactively responding to the antibody-drug conjugate (ADC) market, a next-generation anticancer drug technology. In December last year, it successfully completed an ADC-dedicated production facility and plans to establish an ADC DP production line targeting the first quarter of 2027.

To strengthen competitiveness in drug product (DP) manufacturing, it also plans to build a prefilled syringe mother line by October 2027.

Samsung Life Science Fund continues to invest in promising bio companies. Last year, it invested in BrickBio, Latus Bio, Generate Biomedicines, and the startup venture capital (VC) firm Flagship Pioneering.

Global bases are also expanding. Samsung Biologics has successfully operated sales offices in Boston and New Jersey in the United States. Last year, it opened a sales office in Tokyo, Japan.

Additionally, efforts for ESG management continue, such as joining the Pharmaceutical Supply Chain Initiative (PSCI) in August last year, the first in the domestic CDMO industry, to support the pharmaceutical and bio industry supply chain.

Samsung Bioepis strengthened its position as a leading global biosimilar company by achieving 1.5 times sales growth and 2.1 times operating profit growth compared to the previous year.

In particular, last year, it significantly expanded its product portfolio in the global market with approvals for Soliris biosimilar (SB12) in Korea and the United States, Eylea biosimilar (SB15) in Korea, the United States, and Europe, and Stelara biosimilar (SB17) in Korea, Europe, and the United States. This maximized milestone revenue (compensation for research and development achievements) from licensing agreements with partners.

Samsung Bioepis currently holds marketing authorization for nine biosimilar products in Europe and eight in the United States. The outlook for this year is also bright. In November last year, it received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency for Prolia and Xgeva biosimilar (SB16), signaling the possibility of final approval this year.

Samsung Bioepis plans to continue sustainable growth in 2025 based on global-level research and development and commercial capabilities. Through partnerships with multinational pharmaceutical companies Sandoz (Stelara biosimilar) and Teva (Soliris biosimilar), it plans to launch new products in the U.S. market, and accelerate development of the Keytruda biosimilar (SB27) by overlapping Phase 1 and Phase 3 clinical trials.

Furthermore, by directly selling Episcle® (Soliris biosimilar), a rare disease treatment, in Korea and Europe, Samsung Bioepis aims to improve patient access to ultra-high-priced biopharmaceuticals and contribute to building a sustainable healthcare system and reducing national health insurance finances through biosimilar development and sales.

This content was produced with the assistance of AI translation services.